The Organon Access Program can contact insurers to request patient-specific coverage and benefits information for BILPREVDA, including whether the plan covers BILPREVDA; deductible, co-insurance, and out-of-pocket maximum amounts; and whether the plan has prior authorization or step therapy requirements.
Billing and coding information is available online as well as sample CMS-1500 and UB-04 claim forms for office and hospital settings.
The Organon Co-pay Assistance Program can support eligible patients* who need help affording the out-of-pocket costs for BILPREVDA. Once enrolled, eligible, privately insured patients can pay as little as $0 per injection. Eligible patients may also receive certain Organon medicines free of charge through the Organon Patient Assistance Program Inc.
*Not all patients are eligible to use the multi-use savings coupon. Certain restrictions apply. Please see terms and conditions.
Organon is committed to helping your patients understand the importance of medication adherence with helpful resources.
†With additional 120-mg doses on Days 8 and 15 of the first month for the treatment of giant cell tumor of bone or hypercalcemia of malignancy.
Computer-generated X-ray depiction of humerus represents one of the common sites of bone metastases.1
BILPREVDA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
BILPREVDA is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
BILPREVDA is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Pre-existing hypocalcemia must be corrected prior to initiating therapy with BILPREVDA. BILPREVDA is contraindicated in patients with known clinically significant hypersensitivity to denosumab products.
Patients receiving BILPREVDA should not receive other denosumab products concomitantly.
Denosumab products can cause severe symptomatic hypocalcemia, and fatal cases have been reported. Pre-existing hypocalcemia must be corrected prior to initiating BILPREVDA. Monitor calcium levels throughout therapy, especially in the first weeks of initiating therapy, and administer calcium, magnesium, and vitamin D as necessary. Concomitant use of calcimimetics and other drugs that can lower calcium levels may worsen hypocalcemia risk, and serum calcium should be closely monitored. Advise patients to contact a health care provider for symptoms of hypocalcemia.
An increased risk of hypocalcemia has been observed in clinical trials of patients with increasing renal dysfunction, most commonly with severe dysfunction (creatinine clearance less than 30 mL/min and/or on dialysis), and with inadequate/no calcium supplementation. Monitor calcium levels and calcium and vitamin D intake.
BILPREVDA is contraindicated in patients with known clinically significant hypersensitivity to denosumab products, including anaphylaxis. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue BILPREVDA therapy permanently.
ONJ has been reported in patients receiving denosumab products, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of ONJ. In clinical trials in patients with cancer, the incidence of ONJ was higher with longer duration of exposure.
A history of tooth extraction, poor oral hygiene, or use of a dental appliance may be predisposing factors to developing ONJ. Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections.
Perform an oral examination and appropriate preventive dentistry prior to the initiation of BILPREVDA and periodically during therapy. Advise patients regarding oral hygiene practices. Avoid invasive dental procedures during treatment with BILPREVDA. Consider temporarily interrupting therapy if an invasive dental procedure must be performed.
Patients who are suspected of having or who develop ONJ while on BILPREVDA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.
Atypical femoral fracture has been reported with denosumab products. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution.
Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (eg, prednisone) at the time of fracture. During BILPREVDA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of BILPREVDA therapy should be considered, pending a risk/benefit assessment, on an individual basis.
Clinically significant hypercalcemia requiring hospitalization and complicated by acute renal injury has been reported in denosumab-treated patients with GCTB and in patients with growing skeletons. Hypercalcemia has been reported within the first year after treatment discontinuation. After treatment is discontinued, monitor patients for signs and symptoms of hypercalcemia, assess serum calcium periodically, reevaluate the patients’ calcium and vitamin D supplementation, and treat appropriately.
MVF have been reported following discontinuation of treatment with denosumab products. Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or prior fractures. When BILPREVDA treatment is discontinued, evaluate the individual patient’s risk for vertebral fractures.
Based on data from animal studies and its mechanism of actions, denosumab products can cause fetal harm when administered to a pregnant woman.
Verify the pregnancy status of females of reproductive potential prior to the initiation of BILPREVDA. Advise females of reproductive potential to use effective contraception during therapy, and for at least 5 months after the last dose of BILPREVDA. Advise pregnant women and females of reproductive potential that exposure to BILPREVDA during pregnancy or within 5 months prior to conception can result in fetal harm.
The most common adverse reactions (incidence ≥25%) in patients with bone metastasis from solid tumors were fatigue/asthenia, hypophosphatemia, and nausea. The most common serious adverse reaction was dyspnea. The most common adverse reactions resulting in discontinuation were osteonecrosis and hypocalcemia.
The most common adverse reactions (incidence ≥10%) in patients with multiple myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache. The most common serious adverse reaction was pneumonia. The most common adverse reaction resulting in discontinuation was osteonecrosis of the jaw.
The most common adverse reactions (incidence ≥10%) in patients with GCTB were arthralgia, back pain, pain in extremity, fatigue, headache, nausea, nasopharyngitis, musculoskeletal pain, toothache, vomiting, hypophosphatemia, constipation, diarrhea, and cough. The most frequent serious adverse reactions were osteonecrosis of the jaw, bone giant cell tumor, anemia, pneumonia, and back pain. The most common adverse reaction resulting in discontinuation was osteonecrosis of the jaw.
The most common adverse reactions (incidence >20%) in patients with hypercalcemia of malignancy were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea.
Before prescribing BILPREVDA, please read the Prescribing Information.
References:
1. Jayarangaiah A, Kemp AK, Kariyanna PT. Bone Metastasis. StatPearls. NCBI Bookshelf. July 31, 2023. Accessed June 10, 2025. https://www.ncbi.nlm.nih.gov/books/NBK507911/?report=printable
2. Ebbers HC, Fehrmann B, Ottosen M, et al. Batch-to-batch consistency of SB4 and SB2, etanercept and infliximab biosimilars. BioDrugs. 2020;34(2):225-233. doi:10.1007/s40259-019-00402-0
3. Biosimilars in the United States: providing more patients greater access to lifesaving medicines. Biosimilars Council. 2017. Accessed July 25, 2025. https://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf
4. Overview for health care professionals. US Food and Drug Administration. Updated August 1, 2024. Accessed March 13, 2025. https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals
5. Review and approval. US Food and Drug Administration. December 13, 2022. Accessed July 28, 2025. https://www.fda.gov/drugs/biosimilars/review-and-approval
6. Farooki A. NCCN bone health task force: key recommendations. J Natl Compr Canc Netw. 2014;12(5 Suppl):813-816. doi:10.6004/jnccn.2014.0196
7. Reese R, Nanavath SR, Martin J, Travers JB, Rohan CA. A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the Department of Veterans Affairs. J Dermatolog Treat. 2024;35(1):2402912. doi:10.1080/09546634.2024.2402912
8. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–6249s. doi:10.1158/1078-0432.CCR-06-0931
9. Krzeszinski JY, Wan Y. New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci. 2015;36(6):360-373. doi:10.1016/j.tips.2015.04.006
10. Prime Therapeutics. 2023 Medical pharmacy trend report. Issuu. September 12, 2024. Accessed January 29, 2025. https://issuu.com/primetherapeutics/docs/2023_medical_pharmacy_trend_report
11. Sparks G, Lopes L, Montero A, Presiado M, Hamel L. Americans’ challenges with health care costs. KFF. July 11, 2025. Accessed July 29, 2025. https://www.kff.org/health-costs/issue-brief/americans-challenges-with-health-care-costs/#
12. Xgeva Medicare prescription drug coverage. GoodRx. October 2024. Accessed February 12, 2025. https://www.goodrx.com/xgeva/medicare-coverage
13. Data on File. Organon group of companies.
14. Li N, Chu N, Zhu L, et al. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: a randomized phase I study. Clin Transl Sci. 2024;17(12):e70089. doi:10.1111/cts.70089
15. Biosimilars basics for patients. US Food and Drug Administration. May 7, 2024. Accessed September 30, 2025. https://www.fda.gov/drugs/biosimilars/biosimilars-basics-patients
16. Ferrari S, Libanati C, Lin CJF, et al. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. 2019;34(6):1033-1040. doi:10.1002/jbmr.3722
17. Mihara A, Iwanaga R, Muramatsu K, Ihara K, Sakai T. Clinical efficacy and safety of long-term treatment, discontinuation, and extended dosing intervals of denosumab treatment for solid cancer bone metastasis: a retrospective study. J Orthop Sci. 2025;S0949-2658(25)00133-2. doi:10.1016/j.jos.2025.04.012
18. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther. 2022;39(1):58-74. doi:10.1007/s12325-021-01936-y
XGEVA is a trademark registered in the US by Amgen Inc.; Organon is not associated with this trademark owner.
